FRM
REGN icon

Fox Run Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Fox Run Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,413
Closed -$2.48M – 1197
2025
Q3 		$2.48M Buy
+4,413
New +$2.5M 0.39% 9
2025
Q2 		– Sell
-1,734
Closed -$1.1M – 1164
2025
Q1 		$1.1M Buy
+1,734
New +$1.19M 0.17% 172
2024
Q4 		– Sell
-452
Closed -$475K – 1129
2024
Q3 		$475K Buy
+452
New +$503K 0.11% 373
2024
Q2 		– Sell
-721
Closed -$694K – 1020
2024
Q1 		$694K Buy
721
+45
+7% +$42.8K 0.15% 259
2023
Q4 		$594K Buy
676
+363
+116% +$299K 0.15% 236
2023
Q3 		$258K Buy
+313
New +$246K 0.08% 494
2021
Q4 		– Sell
-417
Closed -$252K – 669
2021
Q3 		$252K Buy
+417
New +$259K 0.16% 292
2020
Q4 		– Sell
-376
Closed -$210K – 268
2020
Q3 		$210K Buy
+376
New +$228K 0.53% 111
2018
Q1 		– Sell
-2,953
Closed -$1.11M – 886
2017
Q4 		$1.11M Buy
+2,953
New +$1.2M 0.33% 52
2017
Q1 		– Sell
-1,200
Closed -$441K – 718
2016
Q4 		$441K Buy
+1,200
New +$456K 0.23% 166
2016
Q3 		– Sell
-1,400
Closed -$489K – 650
2016
Q2 		$489K Sell
1,400
-1,300
-48% -$501K 0.24% 136
2016
Q1 		$973K Buy
+2,700
New +$1.11M 0.65% 8

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Fox Run Management's REGN Position: Q4 2025 in Review

Fox Run Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 4,413 shares — an estimated $2.48M sold.

Fox Run Management first reported a position in REGN in Q1 2016 and held it in 12 quarters. The position peaked at $2.48M in Q3 2025. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Fox Run Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Fox Run Management sold 4,413 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $2.48M.
  • Fox Run Management first reported a position in Regeneron Pharmaceuticals in Q1 2016 and held it in 12 quarters.
  • Fox Run Management's Regeneron Pharmaceuticals position peaked at $2.48M in Q3 2025.
  • 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Fox Run Management's 13F filing for Q4 2025, filed 11 Feb 2026.